• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi, DNDi collaborate on new drugs for neglected tropical diseases

Sanofi, DNDi collaborate on new drugs for neglected tropical diseases

May 31, 2011
CenterWatch Staff

French health care company Sanofi has announced a three-year research collaboration agreement with Drugs for Neglected Diseases initiative or DNDi, an independent, nonprofit product development partnership, according to RTT News.

DNDi, formed in 2003, is working to research and develop new treatments for neglected diseases such as Chagas disease, malaria, pediatric HIV and specific helminth-related infections.

DNDi was established by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, Pasteur Institute and Médecins sans Frontières. World Health Organization's tropical disease research program, TDR, acts as a permanent observer to DNDi.

Sanofi said the agreement is built on a previous successful collaboration between Sanofi and DNDi. The two will research new treatments for nine neglected tropical diseases listed by the World Health Organization.

These diseases are kinetoplastid diseases (leishmaniases, Chagas disease and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis and schistosomiasis.

In endemic countries, new, effective tools are urgently required to treat patients with these diseases.

Sanofi, which has been involved in tropical diseases since the 1940s, will initially bring molecules from its libraries into the partnership, and the parties will jointly research on innovative molecular scaffolds.

The core of the agreement is the management of intellectual property generated through the collaboration, the company noted. Sanofi and DNDi will co-own the rights to results produced by the partnership.

Further, the partnership will publish results to ensure access to the wider community of researchers focusing on neglected tropical diseases. The public sector also will benefit from the drugs developed.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing